<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	>

<channel>
	<title>PR Hub &#187; Funxional Therapeutics Limited</title>
	<atom:link href="http://blog.taragana.com/pr/t/funxional-therapeutics-limited/feed/" rel="self" type="application/rss+xml" />
	<link>http://blog.taragana.com/pr</link>
	<description></description>
	<pubDate>Fri, 13 Nov 2009 05:00:00 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.7.1</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action</title>
		<link>http://blog.taragana.com/pr/funxional-successfully-completes-initial-clinical-trial-of-fx125l-an-anti-inflammatory-drug-with-a-novel-mechanism-of-action-3940/</link>
		<comments>http://blog.taragana.com/pr/funxional-successfully-completes-initial-clinical-trial-of-fx125l-an-anti-inflammatory-drug-with-a-novel-mechanism-of-action-3940/#comments</comments>
		<pubDate>Wed, 08 Jul 2009 05:00:00 +0000</pubDate>
		<dc:creator>Prne</dc:creator>
		
		<category><![CDATA[Biotechnology]]></category>

		<category><![CDATA[Clinical Trials / Medical Discoveries]]></category>

		<category><![CDATA[Health]]></category>

		<category><![CDATA[Health Care / Hospitals]]></category>

		<category><![CDATA[Pharmaceuticals]]></category>

		<category><![CDATA[Cambridge]]></category>

		<category><![CDATA[England]]></category>

		<category><![CDATA[Funxional Therapeutics Limited]]></category>

		<category><![CDATA[United Kingdom]]></category>

		<guid isPermaLink="false">http://blog.taragana.com/pr/funxional-successfully-completes-initial-clinical-trial-of-fx125l-an-anti-inflammatory-drug-with-a-novel-mechanism-of-action-3940/</guid>
		<description><![CDATA[CAMBRIDGE, England - Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).

The Phase I, single ascending dose study was conducted in the United States. FX125L was well tolerated [...]]]></description>
		<wfw:commentRss>http://blog.taragana.com/pr/funxional-successfully-completes-initial-clinical-trial-of-fx125l-an-anti-inflammatory-drug-with-a-novel-mechanism-of-action-3940/feed/</wfw:commentRss>
		</item>
	</channel>
</rss>

